Epstein-Barr virus (EBV) infection has been associated with the development of several types of human malignancy. The horizontal transmission of EBV from host to host requires activation of the lytic origin of replication, ori-Lyt. In contrast, transformation of cells by EBV is generally associated with latent viral infection and may require that lytic replication be suppressed. Both of the EBV immediate-early transcriptional activators, BZLF1 (Z) and BRLF1 (R), are required for ori-Lyt replication. However, it is not known whether the role of Z and R is limited to transcriptional activation of ori-Lyt or whether one or both of these proteins also plays a more basic role in replication. In addition, the regulation of ori-Lyt replication by cellular factors has not been well studied. In this grant, we propose to study the regulation of ori-Lyt by viral and cellular factors. We hypothesize that the regulation of ori-Lyt replication plays a role in determining the efficiency of productive EBV infection in different cell types. We have recently shown that Z may interact directly with the viral polymerase processivity factor (BMRF1), suggesting a mechanism by which Z could direct the polymerase complex to ori-Lyt. We have shown that Z can also interact directly with p53 and that this interaction may inhibit replication. We have also obtained preliminary data suggesting that three cellular factors (Spl, NF-Y,and zif268) can bind to essential regions of ori-Lyt and potentially regulate its replicative function. We propose the following specific aims: 1) To examine the role of Z and R in ori-Lyt replication, we will compare the effect of deleting Z and R binding sites in ori-Lyt upon transcription versus replication and will attempt to create mutant Z and R proteins which can activate transcription but not support replication. 2) To determine the role of cellular transcription factors in ori-Lyt replication, we will use a variety of techniques to determine which proteins bind to the known essential sites of ori-Lyt in different cell types and will examine the effect of deleting specific transcription factor binding sites upon ori-Lyt replication versus transcription. 3) To examine the effect of p53 upon ori-Lyt replication, we will determine the location of p53 binding sites in ori-Lyt, examine the effect of mutating these sites in different cell types, and determine if mutant Z which no longer interacts with p53 is more (or less) efficient in supporting ori-Lyt replication. 4) We will construct mutations in the intact virus which eliminate the ability of Z to support ori-lyt replication (but still allow transactivation) and determine how these mutations affect the phenotype in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA019014-17A1
Application #
3749261
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
DeKroon, Robert M; Gunawardena, Harsha P; Edwards, Rachel et al. (2018) Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. MBio 9:
Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6
El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7
Selitsky, Sara R; Marron, David; Mose, Lisle E et al. (2018) Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. mSystems 3:
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Lyons, Danielle E; Yu, Kuan-Ping; Vander Heiden, Jason A et al. (2018) Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication. J Virol 92:
Bigi, Rachele; Landis, Justin T; An, Hyowon et al. (2018) Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 115:E11379-E11387
El-Mallawany, Nader Kim; Villiera, Jimmy; Kamiyango, William et al. (2018) Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer 13:33
Kobayashi, E; Aga, M; Kondo, S et al. (2018) C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes. mSphere 3:
Hopcraft, Sharon E; Pattenden, Samantha G; James, Lindsey I et al. (2018) Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 14:e1007267

Showing the most recent 10 out of 324 publications